CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-01 | Krebs Andreas Director | Grant or award | +21,552 | 21,552 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Stock Option (Right to Buy) | +133,744 | 175,508 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Director's Deferred Share Units | +98,198 | 139,962 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Director's Deferred Share Units | +717,937 | 759,701 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Director's Deferred Share Units | +28,628 | 68,392 | ||
| 2022-06-01 | Vallone Carol A Director | Grant or award | +43,104 | 43,104 | ||
| 2022-06-01 | Vallone Carol A Director | Grant or award · Stock Option (Right to Buy) | +133,744 | 161,587 | ||
| 2022-06-01 | Vallone Carol A Director | Grant or award · Director's Deferred Share Units | +98,198 | 126,041 | ||
| 2022-06-01 | Vallone Carol A Director | Grant or award · Director's Deferred Share Units | +774,673 | 802,516 | ||
| 2022-06-01 | Vallone Carol A Director | Grant or award · Director's Deferred Share Units | +34,353 | 62,196 | ||
| 2022-06-01 | Makes Brigid Director | Grant or award | +64,656 | 158,706 | ||
| 2022-06-01 | Makes Brigid Director | Grant or award · Stock Option (Right to Buy) | +100,308 | 194,358 | ||
| 2022-06-01 | Makes Brigid Director | Grant or award · Director's Deferred Share Units | +361,680 | 643,804 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award | +21,552 | 21,552 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Stock Option (Right to Buy) | +133,744 | 175,508 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Director's Deferred Share Units | +98,198 | 139,962 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Director's Deferred Share Units | +717,937 | 759,701 | ||
| 2022-06-01 | Krebs Andreas Director | Grant or award · Director's Deferred Share Units | +28,628 | 68,392 | ||
| 2022-05-27 | Karlin Dan Chief Medical Officer | Sale | −9,555 | $0.82 | $8K | 4,077,719 |
| 2022-05-25 | Barrow Robert Chief Executive Officer | Sale | −18,415 | $0.77 | $14K | 3,976,894 |
Page 10 of 12 · 225 trades